Skip to main content

Ramon Martí Seves

Institutions of which they are part

Head of group
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Ramon Martí Seves

Institutions of which they are part

Head of group
Neuromuscular and Mitochondrial Pathology
Vall Hebron Institut de Recerca

Projects

Models d'estudi de malalties degudes a manteniment defectuós del DNA mitocondrial

IP: Ramon Martí Seves
Collaborators: Mª Jesus Melia Grimal, Pau Mollá Zaragozá, Javier Francisco Ramón Pasías, Juan Luis Restrepo Vera
Funding agency: Instituto de Salud Carlos III
Funding: 208750
Reference: PI24/00838
Duration: 01/01/2025 - 31/12/2027

Células progenitoras residentes derivadas de músculo esquelético: modelo celular in vitro preferente en el proceso diagnóstico y de investigación traslacional de las enfermedades mitocondriales primarias

IP: Ramon Martí Seves
Collaborators: Juan Luis Restrepo Vera, Laia Perez Lasarte
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: CARLESM/RAMON_MS
Duration: 30/06/2023 - 29/06/2024

Células progenitoras residentes derivadas de músculo esquelético: modelo celular in vitro preferente en el proceso diagnóstico y de investigación traslacional de las enfermedades mitocondriales primarias

IP: Ramon Martí Seves
Collaborators: Juan Luis Restrepo Vera
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 74452.89
Reference: 2024 FI-1 00388
Duration: 01/07/2024 - 30/06/2025

Generation of therapies and biomarkers for the treatment of mitochondrial dysfunction driven neurodegenerative diseases (DRUG4- COXPD1)

IP: Ramon Martí Seves
Collaborators: -
Funding agency: Fundació Institut Bioenginyeria de Catalunya
Funding: 0.01
Reference: T7243
Duration: 02/01/2023 - 31/12/2024

Related news

The projects, selected under the 2026 Health Research and CaixaImpulse Health Innovation calls, address topics ranging from new therapies for childhood neurological disorders and Parkinson’s disease to the treatment of mitochondrial diseases and cancer.

The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

Related professionals

Montserrat Perez Gonzalez

Montserrat Perez Gonzalez

Research technician
Clinical Pharmacology
Read more
Albert Gargallo Margarit

Albert Gargallo Margarit

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Sara Ajanovic Andelic

Sara Ajanovic Andelic

Predoctoral researcher
Infection and immunity in pediatric patients
Read more
Sabina Salicrú Riera

Sabina Salicrú Riera

Predoctoral researcher
Biomedical Research in Gynaecology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.